Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on everolimus armObjective response rate (ORR) was h ...
Morgan Stanley Technology, Media & Telecom Conference 2026 March 5, 2026 1:45 PM ESTCompany ParticipantsEd McGowan ...
HomeLight reports eight spring home-selling tips that can enhance sale prices through effective pricing, timing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results